In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Cellular Biomedicine Group, Inc.. Trade Record

NASDAQ:CBMG Cellular Biomedicine Group, Inc. stock gains 48.00% Exit Jan 23, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CBMG Jan 2, 2018, priceSeries
About Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. It also provides consulting services to companies who seek access to the U.S. capital markets. The company is headquartered in Palo Alto, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
69.50
Entry Date
Jan 2, 2018
Entry Price
12.50
Sell Date
Jan 23, 2018
Sell Price
18.50
Net Gain
48.00%
Hold Time
14 Trading Days